Cartherics Pty Ltd
June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
Cartherics is a pre-clinical stage company developing cell-based products for the treatment of cancer and other intractable diseases such as endometriosis. Its technology platform is based on gene-edited induced pluripotent stem cells (iPSCs), from which it generates natural killer (NK) cells, other immune cells, and extracellular vesicles (EVs) derived from those cells. Its lead product (CTH-401) is an iPSC-derived NK cell carrying a chimeric antigen receptor (CAR) targeting the tumor associated antigen TAG-72. The CTH-401 cells are also modified by the deletion of two genes to make them less susceptible to immunosuppression. The initial indication for CTH-401 is ovarian cancer, for which the Company is in the process of preparing an IND for submission to the FDA. Follow-on CAR-NK cell products (and EVs derived from them) targeting tissue factor (TF) are in development. Both TAG-72 and TF are expressed by a range of different types of solid tumors, as well as in endometriosis.
Company HQ City:
Notting Hill
Company HQ State:
Victoria
Company HQ Country:
Australia
Year Founded:
2015
Lead Product in Development:
CTH-401 (iPSC-derived CAR-NK cell)
CEO
Prof Alan Trounson
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
IND filing
What is your next catalyst (value inflection) update?
H2 2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}